EUCTR2007-002009-31-NL进行中（未招募）不适用
A double blind randomized placebo controlled cross-over study to validate the distinction between women with different levels of attention and valence direction for erotic stimuli, in relation with genital and subjective sexual arousal in healthy female subjects and healthy female subjects with FSD. - VA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1Subjects must have a heterosexual orientation or secondary bisexual orientation
- •2Subjects must be between 21 and 65 years of age
- •3Subjects must have experienced low sexual arousal and / or low sexual desire for at least six months prior to study entry according to DSM IV criteria. The diagnosis will be made by an experienced psychologist/sexologist.
- •4Subjects must have signed the Informed Consent Form.
- •5Inclusion will be following the selection criteria including a, but not limited to, physical examination (including a gynecological examination), medical history, vital signs, pregnancy test and ECG, and by the scoring on the strooptask during familiarization trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1Use of oral contraception containing anti-androgens (Like Diane 35 or Minerva);
- •2Use of oral contraception containing 50 µg estrogen or more;
- •3Pregnancy, or intention to become pregnant during this study (Note: a serum or urine pregnancy test will be performed in all women prior to the administration of study medications);
- •4A pelvic inflammatory disease or an untreated vaginal infection at screening;
- •5Lactating or subjects who have given birth in the previous 6 months;
- •6Previous prolapse and incontinence surgery affecting the vaginal wall;
- •7Women with other unexplained gynecological complaints, such as abnormal uterine bleeding patterns;
- •8History of endocrinological treatment or current endocrinological treatment (with the exception of the use oral contraceptives and of fertility-promoting treatment);
- •9History of neurological treatment or current neurological treatment;
- •10History of serious psychiatric treatment or current psychiatric treatment;
- •11Any underlying cardiovascular condition including unstable angina pectoris, that would preclude sexual activity;
- •12History of myocardial infarction, stroke or life-threatening arrhythmia within the prior 6 months;
- •13Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate > 100 bpm), or other significant abnormality observed on ECG;
- •14Systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg. For subjects with age > 60 years and without diabetic mellitus, familiar hypercholesterolemia or cardiovascular disease: Systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 90 mmHg (According to the CBO-guideline hypertension (CBO.2000a)).
- •15Subjects who are taking strong CYP3A4-inhibitors: ritonavir (HIV-proteaseremmer), ketoconazol en itraconazol
- •16Subjects who are taking less strong CYP3A4-inhibitors: claritromycine, erytromycine en saquinavir
- •17Subjects who are taking CYP3A4-inducers: carbamazepine, fenytoïne, fenobarbital, st Johns Wort, rifampicine
- •18Severe chronic or acute liver disease, history of moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment;
- •19Use of medicinal herb as Ginkgo Biloba and nutrition containing grapefruit;
- •20Subjects who are taking nitrates or nitric oxide donors;
- •21A substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject’s participation in the study; mild or moderately alcohol drinking behavior is allowed, only 12 hours before the experimental days is alcohol drinking not allowed. Three weeks before the start of the experimental day is the taking of any recreational drug not allowed. Smoking is allowed.
- •22Use of any treatment for FSD within the 7 days before visit 1 or during the study, including oral medications or constrictive devices;
- •23Subjects who are illiterate, unwilling or unable to understand and complete the questionnaires;
- •24Any other clinically significant abnormality or condition which in the opinion of investigator would interfere with the participant’s ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if she took part in the trial;
- •25Moderate and severe hearing impairment;
- •26Subjects who are colour blinded.
- •27Subjects who are having botox® (or other equivalents of botox, like dysport) in the facial area within 6 months before the first experimental da
研究者
相似试验
已完成
4 期
A study to assess the effects of Rapid Recovery on the adverse effects of alcohol consumptioACTRN12618001996257Phoenix Pharmaceuticals Pty Ltd25
进行中（未招募）
不适用
A double-blind randomized placebo controlled crossover study of AZD7371 ER 5 mg bid, 20 mg bid and placebo treatment for one week on visceral perception and symptoms in patients with Irritable Bowel SyndromeIrritable Bowel Syndrome (IBS)EUCTR2004-000383-27-SEAstraZeneca AB48
已完成
3 期
A clinical study to evaluate the safety of cassia tora consumption in humansCTRI/2014/11/005160Director60
已完成
不适用
Clinical study to evaluate the effectiveness of A-Hango in reducing alcohol induced veisalgia symptoms in healthy adult social drinkers.CTRI/2022/04/042209Praras Bioscience Pvt Ltd76
已完成
不适用
Polypill Prevention Trial 1Circulatory SystemCardiovascular DiseaseISRCTN36672232Queen Mary University of London (UK)100